Market research
BCDA Biocardia Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- 0.49
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09060U6064
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- 0.49
About
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BCDA discussion.
5 years, 4 months ago
BioCardia, Inc is currently in a long term downtrend where the price is trading 1.7% below its 200 day moving average.
From a valuation standpoint, the stock is 77.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 304.3.
BioCardia, Inc's total revenue sank by 78.6% to $46K since the same quarter in the previous year.
Its net income has increased by 14.6% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 4.9% to $-3M since the same quarter in the previous year.
Based on the above factors, BioCardia, Inc gets an overall score of 2/5.